TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ABBV

AbbVie Inc

Healthcare · Drug Manufacturers - General

264.00$ +0.0% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios ABBV
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Valuation
59.4 18.8 17.2 29.2 25.1 16.7 38.9 20.8 24.3 56.5 73.6 95.9
5.3 4.2 4.0 5.5 4.4 3.9 3.9 4.3 4.9 5.1 5.6 6.6
60.4 24.6 22.0 30.4 13.7 15.6 16.6 26.4 93.7
5.6 5.3 5.2 6.5 5.4 4.8 5.6 5.5 5.9 5.9 6.7 7.6
31.2 14.7 13.2 17.6 21.1 12.9 20.9 12.9 14.1 18.7 25.3 26.5
35.9 13.8 15.6 16.4 11.1 10.3 10.7 10.9 11.8 12.5 17.7 22.8
2.8% 7.2% 6.4% 6.1% 9.0% 9.7% 9.4% 9.1% 8.4% 8.0% 5.7% 4.4%
Margins
77.8% 80.3% 77.2% 75.0% 76.4% 77.6% 66.4% 69.0% 70.0% 62.4% 70.0% 70.2%
17.1% 33.0% 36.4% 33.8% 19.5% 39.0% 24.8% 31.9% 31.2% 23.5% 16.2% 32.8%
8.9% 22.5% 23.2% 18.8% 17.4% 23.7% 10.1% 20.5% 20.4% 9.0% 7.6% 6.9%
14.7% 30.6% 25.6% 33.4% 39.0% 38.4% 36.7% 39.1% 41.8% 40.6% 31.7% 29.1%
Returns
101.8% 130.4% 128.4% 104.2% 35.2% 74.8% 68.5% 46.8% 127.2%
6.4% 9.7% 9.0% 7.5% 9.6% 8.8% 3.1% 7.9% 8.5% 3.6% 3.2% 3.2%
Balance Sheet & Debt
6,656 23,272 31,742 28,065 33,021 26,804 77,782 67,116 54,236 46,571 61,620 62,461
1.9 2.8 3.1 2.7 4.0 2.2 6.3 2.8 2.2 2.7 4.1 3.5
6.3% 7.4% 7.0% 7.2% -14.2% -9.2% 8.7% 10.5% 12.5% 7.7% 2.5% -2.4%
8.6 8.0 7.9 7.3 6.6 5.0 3.7 5.7 20.0
Per Share
1.10 3.14 3.65 3.31 3.68 5.31 2.76 6.50 6.66 2.74 2.41 2.38
12.40 13.96 15.72 17.60 21.19 22.42 27.38 31.62 32.65 30.64 31.77 34.48
1.08 2.41 2.84 3.18 -5.46 -5.51 7.83 8.69 9.72 5.86 1.90 -1.82
1.82 4.28 4.02 5.88 8.27 8.61 10.04 12.37 13.64 12.44 10.06 10.04

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?